ClinicalTrials.gg
Not yet recruitingNCT07806162Updated Sep 8, 2026

Comparison Between Opioid-Free Anaesthesia Versus Opioid Based Anesthesia in Reduction Postoperative Nausea and Vomiting (PONV)After Thoracoscopic Lung Resection.

An interventional study of Opioid Free Anaesthesia and conventential opioid-based anaesthesia (OBA, in PONV, sponsored by Sohag University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Sohag University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The invistigators hypothesized that a protocolized OFA technique would lower the occurance of PONV in patients undergoing thoracoscopic lung surgery compared to standard opioid-based anaesthesia.

02

Conditions studied

03

In context

Postoperative Nausea and Vomiting

638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.

This study's planned enrollment of 120 is close to the median of 112 across 529 interventional studies indexed under Postoperative Nausea and Vomiting.

Browse Postoperative Nausea and Vomiting studies →

Lead sponsor

Sohag University is the lead sponsor of 1,232 studies on the registry; 638 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:-

  • Eligible participants were adults (18-80 years).
  • Prepared for elective thoracoscopic lobectomy or segmentectomy for lung cancer under general anaesthesia

Exclusion Criteria:

  • to any study drug (e.g., heart block, severe liver disease, allergy).
  • Chronic opioid use (>30 MME/day for >3 months).
  • Patients with renal impairment (e \<30 mL/min).
  • Pregnancy.
  • Inability to comprehend pain scales.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Placebo comparator
    conventential opioid-based anaesthesia (OBA, n=60).

    Drug: conventential opioid-based anaesthesia (OBA,

  • Experimental
    opioid free anesthesia( OFA , n=60)

    Drug: Opioid Free Anaesthesia

Interventions

  • DrugOpioid Free Anaesthesia

    The OFA group protocol consists of a combination of intravenous lidocaine, ketamine, dexmedetomidine, and propofol TIVA.

  • Drugconventential opioid-based anaesthesia (OBA,

    The OBA group protocol consists of balanced anaesthesia with fentanyl plus sevoflurane.

06

What researchers measure

Primary outcomes

  1. the occurrence of PONV during the initial 24 hours

    Time frame: 24 hours

Secondary outcomes

  1. total opioid consumption over 24 hour (expressed as morphine milligram equivalents.

    Time frame: 24 hours

  2. pain intensity scores (numerical rating scale NRS 0-10)

    Time frame: 24 hours

  3. recovery quality (QoR-15 score)

    Time frame: 24 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Oct 2026, 1 month later.

Of 181 non-industry interventional studies with no phase under Postoperative Nausea and Vomiting, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 1 month is below that.

Counting every sponsor, half of 181 studies reached it within 13 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2026
First posted
Sep 8, 2026
StartEst.
Sep 2026
Primary completionEst.
Oct 20, 2026
CompletionEst.
Nov 2026
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07806162
Lead sponsor
Sohag University
Responsible party
Islam Mokhtar Ahmed (Assistant professor of Anesthesia and Intensive Care, Sohag University) — Principal investigator
First posted
Sep 8, 2026
Start date
Sep 2026 (estimated)
Primary completion
Oct 20, 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Sep 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion